NDA 022052 · Chiesi
Zyflo Cr
Zileuton · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 31, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
May 30, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
1 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZYFLO CR · ZILEUTON 600MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Zileuton" as an intervention, any sponsor and status, largest first.
- Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICSPivotal-lookingTerminated
Critical TherapeuticsIndustry
NCT00486343 · 400 participants (planned) · Start Jul 2007 · Primary completion May 2008
Drug: Zileuton CR; Placebo · For: Asthma
Sites: Lexington, Massachusetts
- A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term TherapyPivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT01125748 · 176 participants · Start May 2010 · Primary completion Aug 2013
Drug: Omalizumab; Placebo and 1 more · For: Allergic Asthma
Sites: Huntsville, Alabama; Little Rock, Arkansas; Bakersfield, California · 100 sites in all
- Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung CancerPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00070486 · 140 participants · Start Dec 2003 · Primary completion Dec 2006
Drug: carboplatin; celecoxib and 2 more · For: Lung Cancer
Sites: Anniston, Alabama; La Jolla, California; Los Angeles, California · 75 sites in all
- Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical TrialPivotal-lookingStatus unknown
Postgraduate Institute of Dental Sciences RohtakAcademic, hospital or other
NCT04996199 · 132 participants (planned) · Start Sep 18, 2021 · Primary completion Dec 31, 2021
Drug: Oxcarbazepine; Carbamazepine · For: Trigeminal Neuralgia
Sites: Rohtak, India · 2 sites in all
- Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)Pivotal-lookingTerminated
University of MinnesotaAcademic, hospital or other
NCT00493974 · 119 participants · Start Mar 2007 · Primary completion Dec 2008
Drug: Zileuton; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 18 sites in all
Critical TherapeuticsIndustry
NCT00098358 · 90 participants · Start Nov 2004
Drug: Zileuton · For: Acne Vulgaris
Sites: San Diego, California; Newnan, Georgia; Louisville, Kentucky · 12 sites in all
National Cancer Institute (NCI)NIH
NCT01021215 · 84 participants · Start May 2010 · Primary completion Aug 2012
Drug: Zileuton; Celecoxib · For: Tobacco Use Disorder
Sites: New York, New York; Houston, Texas
National Cancer Institute (NCI)NIH
NCT02348203 · 63 participants · Start Jan 13, 2016 · Primary completion Feb 22, 2019
Drug: Aspirin; Zileuton · For: Tobacco Use Disorder
Sites: Tucson, Arizona; Boston, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Genome-wide association study of leukotriene modifier response in asthma.
Dahlin A, Litonjua A, Irvin CG, et al. · Pharmacogenomics J 2016 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.
Dekhuijzen PN, Bootsma GP, Wielders PL, et al. · Eur Respir J 1997 · Clinical Trial, Randomized Controlled Trial
- 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci.
Tantisira KG, Lima J, Sylvia J, et al. · Pharmacogenet Genomics 2009 · Controlled Clinical Trial, Research Support, N.I.H., Extramural
- Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics.
Hasday JD, Meltzer SS, Moore WC, et al. · Am J Respir Crit Care Med 2000 · Clinical Trial, Randomized Controlled Trial
- Neuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review.
Law SWY, Wong AYS, Anand S, et al. · Drug Saf 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma.
O'Connor BJ, Löfdahl CG, Balter M, et al. · Respir Med 2007 · Multicenter Study, Randomized Controlled Trial
Sponsor: Chiesi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.